Servier Acquires Day One Biopharmaceuticals in $2.5 Billion All-Cash Deal
French pharmaceutical group Servier has agreed to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share, valuing the deal at approximately $2.5 billion. The offer represents a 68% premium to DAWN's closing price on Thursday and an 86% premium to its 30-day volume-weighted average price.
DAWN stock surged 66% in premarket trading following the announcement on March 6, 2026. Day One's board unanimously approved the transaction, recommending shareholders accept the tender offer. The deal is expected to close in Q2 2026, pending antitrust clearance and majority tender conditions.
The acquisition removes financing contingencies, a common hurdle in such transactions. Servier's move signals aggressive expansion in the biopharmaceutical sector, leveraging Day One's pipeline for future growth.